Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.9252W HIGH $35.58
Volume
913.51 K
Value Traded
37.07 M
Short % Float
20.88%
+9.79%Week
-11.14%1 Month
-33.94%3 Month
-25.13%6 Month
-90.2%5 Year
+131.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
821.88 M
EPS (TTM)
-15.29
P/E Ratio
-
Ent. Value
1.05 B
Total Shares
68.58 M
Float Shares
67.96 M
Insiders
0.90%
Institutions
121.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
QDEL Catalyst Timeline
Dated clinical, regulatory and corporate events for QuidelOrtho Corporation
Past FDA Catalysts and PDUFA Decisions
How QDEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
QuidelOrtho Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QDEL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bowman Ronald LeeOfficer (Chief Human Resources Officer) | Option | 2,566 5,941 held | $0.00 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QDEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.2 % (-60 %) | 1.67 M | 101.76 K | -44.84% ( -82.73 K) |
QDEL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QDEL ranks across every disease it competes in
Competitive Position is a premium feature
See how QDEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQDEL News
QDELEarly Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
QuidelOrtho Corporation's latest podcast episode discusses strategies to lower sepsis rates in emergency medicine. Hosted by Josh Casey, the episode features Chris Sanchez, who shares insights on the importance of swift diagnosis and the use of serial procalcitonin testing. These strategies aim to improve treatment decisions and patient outcomes in critical care settings.
Read more →QDELFaster Answers, Better Decisions: ADLM 2026 Highlights
QuidelOrtho Corporation's latest Science Bytes podcast episode highlights key insights from the 2026 ADLM Annual Conference. Experts discuss advancements in molecular diagnostics, including ultra-fast RT-PCR technology and the role of procalcitonin in antibiotic stewardship. The episode emphasizes the importance of rapid, actionable information for clinicians to improve patient outcomes.
Read more →QDEL▼ -24.7%on this news
QuidelOrtho Reports Second Quarter 2026 Financial Results
QuidelOrtho Corporation reported a 3% increase in total revenue for Q2 2026, driven by growth in Labs and Point of Care segments. However, the company experienced a GAAP net loss of $93 million and revised its full-year financial guidance downward due to challenges in the Chinese market and a softer global respiratory environment. Despite these setbacks, the company remains committed to improving cash conversion and strengthening its balance sheet.
Read more →QDELQuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho Corporation will announce its financial results for the second quarter of 2026 on August 6, 2026. Following the announcement, a conference call will take place to discuss the results. Interested parties can access the call through the company's Investor Relations webpage. QuidelOrtho continues to focus on advancing diagnostic solutions.
Read more →QDELBeyond Fentanyl: How the Drug Crisis Is Changing
QuidelOrtho Corporation's latest podcast episode discusses the evolving drug overdose crisis, highlighting a decline in overdose deaths while addressing ongoing challenges. The episode features insights on counterfeit medications, polysubstance use, and emerging synthetic opioids. It emphasizes the importance of collaboration between laboratories and emergency departments to enhance toxicology testing and patient care.
Read more →QDELQuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation announced the approval of an Inducement Grant of 356,555 restricted stock units (RSUs) to Micah Young, the new Chief Financial Officer. This grant, approved by the Compensation Committee, is part of the 2026 Inducement Plan and aims to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on Mr. Young's continued employment.
Read more →QDELQuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young succeeds Joseph M. Busky, who will assist in the transition. Young has extensive experience in medical technology finance and aims to enhance profitability and shareholder value at QuidelOrtho.
Read more →QDELQuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
QuidelOrtho and the Allo Hope Foundation have announced a collaboration to enhance prenatal care for women facing maternal red blood cell alloimmunization. This partnership aims to provide education, early testing, and improved connections between healthcare providers and patients. The initiative seeks to address gaps in care, particularly for underserved populations, and will produce educational materials for families and lab technicians.
Read more →QDELWhen Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho Corporation has released a podcast episode discussing hemolytic disease of the fetus and newborn (HDFN), emphasizing the impact of maternal alloimmunization. The episode highlights the importance of awareness, timely diagnostics, and coordinated care to improve outcomes. Despite advancements, significant gaps in understanding and care persist, affecting patient management.
Read more →QDELQuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
QuidelOrtho Corporation announced its participation in two upcoming investor conferences in June 2026. The management team will present at the William Blair 46th Annual Growth Stock Conference and engage in a fireside chat at the Jefferies Global Healthcare Conference. Interested parties can access the events via the company's Investor Relations page.
Read more →QDEL▼ -6%on this news
QuidelOrtho Reports First Quarter 2026 Financial Results
QuidelOrtho Corporation reported its first-quarter financial results for 2026, highlighting a weaker respiratory season and disruptions in key markets. Despite these challenges, the company remains optimistic about its growth prospects, particularly following its acquisition of LEX Diagnostics and the launch of new products. The company has updated its financial guidance for the year, factoring in current market dynamics.
Read more →QDEL▼ -5.5%on this news
Understanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Corporation's latest podcast episode discusses the concerning rise in congenital syphilis cases in the U.S., despite a decline in early-stage infections. Hosted by Josh Casey, the episode features insights from Andrea Ott-Vasconi on CDC data and emphasizes the need for improved diagnostic strategies and healthcare workflows. The discussion highlights missed screening opportunities and actionable steps to enhance prenatal care.
Read more →QDELTTP Group Announces the Sale of LEX Diagnostics
TTP Group has announced the sale of LEX Diagnostics. Details regarding the transaction and its implications for TTP Group and LEX Diagnostics are not provided in the article. The announcement suggests a strategic move by TTP Group, although specifics are lacking.
Read more →QDELQuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation has successfully acquired LEX Diagnostics for approximately $100 million, enhancing its molecular diagnostics capabilities. The LEX VELO System, which has received FDA clearance, offers rapid RT-PCR testing for Influenza A, Influenza B, and COVID-19. The company plans to launch this system commercially in the U.S. later this year, aiming to improve patient outcomes through faster diagnostics.
Read more →QDEL▼ -27.5%on this newsshared move
QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
QuidelOrtho Corporation announced preliminary unaudited revenue of $615-$620 million for Q1 2026, driven by a weaker respiratory season and slower sales in China. The company remains optimistic about its core business, which constitutes over 70% of total revenue. However, it faces challenges from external factors, including geopolitical issues and reimbursement rate changes. A detailed financial report is expected on May 5, 2026.
Read more →QDELNathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky, who has over 25 years of experience in legal and governance roles, succeeds Michelle Hodges, who is retiring. He aims to support the company's mission of advancing diagnostics and improving patient care.
Read more →QDELFaster Cardiac Answers with High‑Sensitivity Troponin
QuidelOrtho Corporation has launched episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom. The episode discusses the impact of high-sensitivity troponin on early cardiac diagnosis and its role in enhancing emergency department efficiency. This advancement is expected to significantly improve patient care in acute settings.
Read more →QDELQuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
QuidelOrtho Corporation announced that its management team will present at the 47th Annual Raymond James Institutional Investor Conference on March 3, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations page. QuidelOrtho continues to focus on advancing in vitro diagnostics to improve patient care.
Read more →About QuidelOrtho Corporation
Headquarters9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next QDEL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime